iOMEDICO AG: Breast Neoplasms trials
The registry lists 11 Breast Neoplasms studies with iOMEDICO AG as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 2 1Phase 3 2Phase 4 1No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast CancerRecruitingNCT07563595
- Breast Cancer Registry PlatformRecruitingNCT03417115
- Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.CompletedNCT05253911
- Patient Preference for Pegfilgrastim (Neulasta®) Application FormsCompletedNCT03619993Not applicable
- Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First LineCompletedNCT03462251Phase 3
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompletedNCT02894398Phase 2
- Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate CancerCompletedNCT02410044
- Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabCompletedNCT02248571Phase 4
- Non-interventional Study With Nab-Paclitaxel (Abraxane®)CompletedNCT01689610
- Tumour Registry Breast CancerCompletedNCT01351584
- Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast CancerCompletedNCT00868634Phase 3